Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas

BMC Cancer

Table 4 Serum levels of fibulin-4, CA-125 and CA19-9 in patients with ovarian tumor

	N	Fibulin-4(ng/ml)	P	CA-125(U/ml)	P	CA19-9(U/ml)	P
Control	40	29.54 ± 16.17		33.32 ± 24.55		35.67 ± 15.59
Benign	60	38.15 ± 18.43	>0.05	33.16 ± 16.23	>0.05	34.89 ± 17.26	>0.05
Pathology type			>0.05		>0.05		>0.05
Serous cystadenoma	25	37.26 ± 12.54		30.51 ± 10.83		36.85 ± 16.27
Mucinous cystadenoma	22	36.75 ± 14.32		35.24 ± 12.69		33.92 ± 14.78
Endometrioid tumor	13	39.26 ± 19.73		32.76 ± 15.93		31.61 ± 13.41
Carcinoma	160	267.06 ± 238.71	<0.05	231.60 ± 205.47	<0.05	158.21 ± 124.59	<0.05
Pathology type			>0.05		<0.05		<0.05
Serous cystadenocarcinoma	58	273.65 ± 215.87		366.22 ± 216.54		97.32 ± 31.13
Mucinous cystadenocarcinoma	56	259.68 ± 211.69		144.38 ± 95.53		275.63 ± 107.69
Endometrioid carcinoma	46	265.72 ± 207.94		138.46 ± 84.95		89.86 ± 49.37
Cell differentiation			<0.05		<0.05		<0.05
High and Medium	88	104.58 ± 83.86		123.86 ± 90.22		87.45 ± 55.36
Low	72	363.29 ± 239.63		378.29 ± 197.34		255.64 ± 158.12
Tumor stage			<0.05		<0.05		<0.05
Low stage	74	113.31 ± 96.05		128.73 ± 85.59		73.59 ± 40.64
High stage	86	364.37 ± 243.92		388.61 ± 216.33		247.38 ± 146.55
Nodal status			<0.05		<0.05		<0.05
Positive	83	353.94 ± 214.37		376.48 ± 225.64		268.93 ± 117.32
Negative	77	101.55 ± 86.81		131.45 ± 99.56		92.78 ± 61.19

ISSN: 1471-2407